Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US
- Lexaria Bioscience recently received four new patents granted in Canada and the United States
- In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD
- So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide
- The strong portfolio gives the company the necessary impetus and peace of mind to pursue multiple large markets, starting with the multi-billion dollar cardiovascular drugs market
- The company has conducted five human clinical studies that have provided insights into the potential of DehydraTECH-CBD to reduce blood pressure
Lexaria Bioscience’s (NASDAQ: LEXX) intellectual property (“IP”) rests on a strong foundation of granted patents worldwide, a foundation that was recently strengthened by new patents granted in North America. The company, which is developing its patented DehydraTECH(TM) technology platform with the intention of availing it to the masses as an additional step in the manufacturing or processing of active pharmaceutical ingredients (“APIs”) with better bioavailability and bioabsorption properties, celebrated the receipt of four new patents granted in Canada and the United States (https://nnw.fm/8LKBd ).
In Canada, the company has been granted two new patents, the first for Patent Family #1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof. According to the company, this is the first patent for this Patent Family issued in Canada, but the 18th patent in this family worldwide. The second patent granted falls under the company’s Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof and is the company’s second patent in this Patent Family, following a similar issuance in Australia.
Across the border in the United States, Lexaria received two new hypertension-related patents, both under its Patent Family #21. The first covers Pharmaceutical Compositions and Methods for Treating Hypertension, while the second is for non-pharmaceutical Compositions and Methods for Treating Hypertension. The company expects these two patents to reinforce its commercial opportunities in both pharmaceutical and consumer markets.
The two new hypertension-related patents come at a time when the company is looking to file its Investigational New Drug (“IND”) application seeking approval from the Food and Drug Administration (“FDA”) to commence the formal and registered study HYPER-H23-1, a Phase 1b evaluation of DehydraTECH-CBD for hypertension, later this year. In fact, Lexaria believes these patents “could be of particular importance related to the company’s pursuit of utilizing DehydraTECH-CBD in relation to our expected upcoming FDA IND application.”
Once approved, the FDA-registered IND program will build on positive data from five hypertension-focused human clinical trials, which evidenced lower blood pressure among participants who received DehydraTECH-processed CBD.
The company’s first human study of 2021, HYPER-H21-1, evidenced a reduction in BP across both male and female volunteers, with the drop most pronounced within the first 10-50 minutes after dosing (https://nnw.fm/d2mS9). HYPER-H21-2, a 16-person study, evidenced up to a 23% average drop in overnight blood pressure and reduced arterial stiffness (https://nnw.fm/rphtF ), while HYPER-H21-3, also a 16-person study, showed that DehydraTECH-CBD’s use reduced pulmonary artery systolic pressure by about 5 mmHg or 41% overall among male participants (https://nnw.fm/r3mw2 ).
The company then conducted the HYPER-H21-4 study, its most comprehensive study yet, involving 66 participants. This fifth study evidenced the exceptional safety and tolerability profile of DehydraTECH-CBD, with the formulation resulting in a statistically significant lowering of 24-hour ambulatory blood pressure. The company also observed that the formulation lowered patients’ BP throughout the entire study duration (5 weeks) and that it was effective at lowering the BP among patients who were taking other antihypertensive drugs as well as those who were not taking any such drugs (https://nnw.fm/YJKEe ). The company has also released additional findings from this study, adding to its list of successes announced in 2023.
So far, on the IP front, for example, the company has received seven new granted patents in the current financial year (2023), which commenced September 1, 2022, six of which have been awarded in calendar 2023. As a result, Lexaria now holds 34 granted patents worldwide. The company has achieved considerable intellectual property protection through this existing patent portfolio, giving it the necessary impetus and peace of mind to pursue multiple large markets, including the cardiovascular drugs market, which is projected to grow at a 3.1% CAGR from $153.6 billion in 2022 to $173.48 billion by 2026 (https://nnw.fm/5GnHn ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience recently received four new patents granted in Canada and the United States
- In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD
- So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide
- The strong portfolio gives the company the necessary impetus and peace of mind to pursue multiple large markets, starting with the multi-billion dollar cardiovascular drugs market
- The company has conducted five human clinical studies that have provided insights into the potential of DehydraTECH-CBD to reduce blood pressure
Lexaria Bioscience’s (NASDAQ: LEXX) intellectual property (“IP”) rests on a strong foundation of granted patents worldwide, a foundation that was recently strengthened by new patents granted in North America. The company, which is developing its patented DehydraTECH(TM) technology platform with the intention of availing it to the masses as an additional step in the manufacturing or processing of active pharmaceutical ingredients (“APIs”) with better bioavailability and bioabsorption properties, celebrated the receipt of four new patents granted in Canada and the United States (https://nnw.fm/8LKBd ).
In Canada, the company has been granted two new patents, the first for Patent Family #1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof. According to the company, this is the first patent for this Patent Family issued in Canada, but the 18th patent in this family worldwide. The second patent granted falls under the company’s Patent Family #8: Compositions Infused with Nicotine Compounds and Methods of Use Thereof and is the company’s second patent in this Patent Family, following a similar issuance in Australia.
Across the border in the United States, Lexaria received two new hypertension-related patents, both under its Patent Family #21. The first covers Pharmaceutical Compositions and Methods for Treating Hypertension, while the second is for non-pharmaceutical Compositions and Methods for Treating Hypertension. The company expects these two patents to reinforce its commercial opportunities in both pharmaceutical and consumer markets.
The two new hypertension-related patents come at a time when the company is looking to file its Investigational New Drug (“IND”) application seeking approval from the Food and Drug Administration (“FDA”) to commence the formal and registered study HYPER-H23-1, a Phase 1b evaluation of DehydraTECH-CBD for hypertension, later this year. In fact, Lexaria believes these patents “could be of particular importance related to the company’s pursuit of utilizing DehydraTECH-CBD in relation to our expected upcoming FDA IND application.”
Once approved, the FDA-registered IND program will build on positive data from five hypertension-focused human clinical trials, which evidenced lower blood pressure among participants who received DehydraTECH-processed CBD.
The company’s first human study of 2021, HYPER-H21-1, evidenced a reduction in BP across both male and female volunteers, with the drop most pronounced within the first 10-50 minutes after dosing (https://nnw.fm/d2mS9). HYPER-H21-2, a 16-person study, evidenced up to a 23% average drop in overnight blood pressure and reduced arterial stiffness (https://nnw.fm/rphtF ), while HYPER-H21-3, also a 16-person study, showed that DehydraTECH-CBD’s use reduced pulmonary artery systolic pressure by about 5 mmHg or 41% overall among male participants (https://nnw.fm/r3mw2 ).
The company then conducted the HYPER-H21-4 study, its most comprehensive study yet, involving 66 participants. This fifth study evidenced the exceptional safety and tolerability profile of DehydraTECH-CBD, with the formulation resulting in a statistically significant lowering of 24-hour ambulatory blood pressure. The company also observed that the formulation lowered patients’ BP throughout the entire study duration (5 weeks) and that it was effective at lowering the BP among patients who were taking other antihypertensive drugs as well as those who were not taking any such drugs (https://nnw.fm/YJKEe ). The company has also released additional findings from this study, adding to its list of successes announced in 2023.
So far, on the IP front, for example, the company has received seven new granted patents in the current financial year (2023), which commenced September 1, 2022, six of which have been awarded in calendar 2023. As a result, Lexaria now holds 34 granted patents worldwide. The company has achieved considerable intellectual property protection through this existing patent portfolio, giving it the necessary impetus and peace of mind to pursue multiple large markets, including the cardiovascular drugs market, which is projected to grow at a 3.1% CAGR from $153.6 billion in 2022 to $173.48 billion by 2026 (https://nnw.fm/5GnHn ).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
